2,2,2-三氯-1-[4-(2-苯基乙酰基)-1H-吡咯-2-基]-1-乙酮 | 338394-85-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2,2,2-三氯-1-[4-(2-苯基乙酰基)-1H-吡咯-2-基]-1-乙酮
• 英文名称: 4-(phenylacetyl)-2-(trichloroacetyl)pyrrole
• 英文别名: 2,2,2-trichloro-1-(4-phenylacetyl-1H-pyrrol-2-yl)-ethanone；2,2,2-trichloro-1-[4-(2-phenylacetyl)-1H-pyrrol-2-yl]-1-ethanone；2,2,2-trichloro-1-[4-(2-phenylacetyl)-1H-pyrrol-2-yl]ethanone
• CAS: 338394-85-7
• 化学式: C₁₄H₁₀Cl₃NO₂
• 分子量: 330.598
• InChiKey: JJTYUDUQOXRRFV-UHFFFAOYSA-N

物化性质

• 沸点：
  484.8±45.0 °C(Predicted)
• 密度：
  1.464±0.06 g/cm3(Predicted)
• 溶解度：
  28.1 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  49.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2,2-三氯-1-[4-(2-苯基乙酰基)-1H-吡咯-2-基]-1-乙酮 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 乙腈 为溶剂， 反应 1.67h， 生成 ethyl 5,6,6a,7,7a-pentahydro-1-(2-phenylacetyl)-4H-cyclobuta[hi]indolizine-4-carboxylate
  参考文献：
  名称：

  The Intramolecular Photometathesis of Pyrroles

  摘要：

  UV irradiation of various electron deficient pyrrole derivatives induces a novel methathesis sequence resulting in selective cleavage of the 2,3-pyrrole bond. The overall sequence has been shown to proceed by two discrete wavelength-dependent steps involving sequential [2+2] cyclobutane formation followed by photochemically mediated retro-[2+2] to the products.

  DOI：

  10.1021/ja070254l
• 作为产物：
  描述：

  2-(三氯乙酰)吡咯 、 苯乙酰氯 在 三氯化铝 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 以60%的产率得到2,2,2-三氯-1-[4-(2-苯基乙酰基)-1H-吡咯-2-基]-1-乙酮
  参考文献：
  名称：

  Heterocyclic inhibitors of ERK2 and uses thereof

  摘要：

  本文描述了一些化合物，这些化合物可用作蛋白激酶抑制剂，其化学式如下： 1 其中Z 1 和Z 2 分别独立地为氮或CH，环A，T m R 1 ，QR 2 ，U n R 3 和Sp如规范中所述。这些化合物特别适用于ERK2的抑制剂，并用于治疗通过蛋白激酶抑制剂缓解的哺乳动物疾病，特别是癌症、炎症性疾病、再狭窄、糖尿病和心血管疾病等疾病。

  公开号：

  US20030092714A1

文献信息

• [EN] PYRROLE DERIVATIVES AS INHIBITORS OF ERK2 AND USES THEREOF<br/>[FR] DERIVES DE PYRROLE UTILISES EN TANT QU'INHIBITEURS DE ERK2 ET LEURS UTILISATIONS
  申请人：VERTEX PHARMA

  公开号：WO2003091246A1

  公开（公告）日：2003-11-06

  Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 Are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.

  本文描述了作为蛋白激酶抑制剂有用的化合物，其化学式为：其中A1、A2、TmR1、X、R2、R3、R9、R12和R13如规范中所述。这些化合物特别适用于抑制ERK2、Aurora2、GSK3、CDK2、AKT3和ROCK蛋白激酶，用于治疗哺乳动物中受蛋白激酶抑制剂缓解的疾病，特别是癌症、神经退行性疾病、炎症性疾病、再狭窄、糖尿病和心血管疾病等疾病。
• Pyrazole compositions useful as inhibitors of ERK
  申请人：——

  公开号：US20040102506A1

  公开（公告）日：2004-05-27

  Described herein are compounds that are useful as protein kinase inhibitors having the formula: 1 where R 1-4 , Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

  本文描述了一些有用的蛋白激酶抑制剂化合物，其化学式为：1，其中R1-4、Q和T在规范中有描述。这些化合物可用于治疗哺乳动物的疾病状态，这些疾病状态可以通过蛋白激酶抑制剂得到缓解，特别是如癌症、炎症性疾病、再狭窄和心血管疾病等疾病。
• Compositions useful as inhibitors of ERK
  申请人：——

  公开号：US20030049820A1

  公开（公告）日：2003-03-13

  This invention provides a method of treating a disease state in mammals that is alleviated by treatment with a protein kinase inhibitor, especially an ERK inhibitor, which method comprises administering a compound having the pharmacophoric features Grp1, Grp2 and Grp3: 1 Grp 1 is an optionally substituted aryl or aliphatic group; Grp 2 is a heteroaromatic ring having one to three nitrogens, said ring comprising a hydrogen bond acceptor HBA2 optionally bonded to a hydrogen bond donor HBD2, and Grp3 is a heteroaromatic ring comprising a hydrogen bond donor HBD1, with distances between the pharmacophoric features defined in the specification. The method is useful for treating cancer, stroke, diabetes, hepatomegaly, cardiovascular disease, Alzheimer's disease, cystic fibrosis, viral disease, autoimmune diseases, atherosclerosis, restenosis, psoriasis, allergic reactions, inflammation, neurological disorders or a hormone-related disease.

  本发明提供了一种治疗哺乳动物疾病状态的方法，该状态通过蛋白激酶抑制剂，特别是ERK抑制剂的治疗得以缓解，该方法包括给予具有Grp1，Grp2和Grp3药效特征的化合物：1Grp 1是可选择取代的芳基或脂肪基；Grp 2是具有一到三个氮原子的杂环芳基环，该环包括一个氢键受体HBA2，可选择地与一个氢键供体HBD2结合，Grp3是一个杂环芳基环，包括一个氢键供体HBD1，药效特征之间的距离在规范中定义。该方法可用于治疗癌症、中风、糖尿病、肝大、心血管疾病、阿尔茨海默病、囊性纤维化、病毒性疾病、自身免疫疾病、动脉粥样硬化、再狭窄、牛皮癣、过敏反应、炎症、神经系统疾病或激素相关疾病。
• Pyrazole compositions useful as inhibitors of erk
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US07056944B2

  公开（公告）日：2006-06-06

  Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

  本文描述了一些具有下列公式的蛋白激酶抑制剂化合物：其中R1-4，Q和T在规范中有描述。这些化合物可用于治疗哺乳动物中由蛋白激酶抑制剂缓解的疾病状态，特别是癌症、炎症性疾病、再狭窄和心血管疾病等疾病。
• PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF ERK
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1200422A2

  公开（公告）日：2002-05-02